NCT01405261View on ClinicalTrials.gov

Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

101

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
DiabetesDiabetes Mellitus, Type 2Healthy
Interventions
DRUG

oral NNC 0113-0987

Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.

DRUG

oral NNC 0113-0987

Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.

DRUG

I.v. NNC 0113-0987

Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.

DRUG

oral placebo

Subjects will be randomised to receive a single dose of placebo.

Trial Locations (1)

NG11 6JS

Nottingham

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT01405261 - Trial Investigating the Safety of NNC 0113-0987 in Healthy Male Subjects | Biotech Hunter | Biotech Hunter